サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1440051

mRNAワクチン・治療 - 世界市場の考察、競合情勢、市場予測（2030年）

mRNA Vaccine and Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
mRNAワクチン・治療 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のmRNAワクチン・治療の市場規模は、2023年に712億6,300万米ドルとなり、2024年～2030年の予測期間にCAGRで-34.01％の成長が見込まれます。mRNAワクチン・治療の需要は主に、突然のパンデミック発生に対する防御需要の高まりや、世界中の感染症に関連する患者の増加、さまざまな適応症に向けた進行中の臨床試験の増加などにより後押しされており、2024年～2030年の予測期間の市場成長にプラスの影響をもたらしています。

mRNAワクチン・治療の市場力学

COVID-19のような突発的なパンデミックの発生を予防し、世界の人々に免疫を発生させるワクチンに対する需要の高まりは、mRNAワクチン・治療市場の全体的な成長を促進する主な要因の1つです。COVID-19ワクチンは、重症化、入院、さらには死亡から人々を守る上で非常に効果的です。mRNAワクチンは、その新しい技術により安全性が高く、ウイルスなどの感染性物質に対する免疫作りに役立ち、重症化する可能性のある疾患を経験することなく抗体反応を起こすと考えられています。

ウイルスは時間とともに絶えず変化し、新しい特徴を持つ亜種が出現する可能性があります。そのため、ワクチンは重篤な疾患の発症から人々を守り続けています。

2022年8月、米国食品医薬品局（FDA）はPfizer-BioNTechのmRNA COVID-19ワクチンを承認しました。12歳以上の人々のCOVID-19疾患の予防を目的として、Comirnatyの名称で販売されました。

さらに、認知、研究活動、資金調達の増加により、mRNAワクチン・治療の採用が増加しているため、主要企業は将来の疾病発生から身を守るために革新的なアプローチを拡大させる可能性があり、このことがmRNAワクチン・治療市場の今後数年間の全体的な成長を促進すると予測されています。

しかし、厳格な規制当局の承認や代替技術を用いた既存ワクチンの存在などが、予測期間のmRNAワクチン・治療市場の成長を抑制する可能性があります。

COVID-19パンデミックは、mRNAワクチン・治療の市場成長にプラスの影響を与えました。COVID-19患者が激増したピークには、医療機関や企業はmRNAワクチンを早急に開発するための研究活動に熱心に取り組み、ワクチン開発プロセスを促進するためにさまざまな多国籍企業や政府からも資金援助を受けていました。初期段階では、ロックダウンや国境閉鎖などにより、原材料や包装資材、消耗品、機器が不足し、mRNAワクチンの生産が妨げられました。しかし、mRNAをベースとしたものを含むCOVID-19ワクチンに関する研究開発活動は、主要企業によって活発に行われていました。世界的なパンデミック（COVID-19など）に発展する可能性があるため、新たな疾患が世界中で生命と経済にもたらす課題を考慮すると、mRNAワクチンの研究開発は、これらの疾患の予防対策として不可欠です。パンデミック後は、ワクチンの導入、医療および製薬部門における活動の再開、さらなる感染症発生に対する戦略的計画に対する各国政府の注目の高まりにより、mRNAワクチン市場は予測期間に飛躍的な成長が見込まれています。

mRNAワクチン・治療市場のセグメント分析

mRNAワクチン・治療市場のワクチンタイプセグメントでは、自己増幅型mRNAベースワクチンカテゴリが2023年に大きな収益シェアを獲得すると予測されます。これは主に、自己増幅型mRNAベースのワクチンには多くの利点があり、研究開発活動が活発化しているためです。

自己増幅型mRNAベースのワクチンは、「自己増幅」設計により少量投与が可能なため、保管が容易であり、コスト削減にも役立ちます。自己増幅型mRNAワクチンは、理想的にはパンデミック期間中に投与される2回の一次投与に取って代わるものであり、従来の同種ワクチンよりもさらに明確な利点があります。現在のmRNAワクチンで奨励されているように、数ヵ月後のブースター投与はなおも正当化される可能性があります。自己増幅型mRNAは、より耐久性のある免疫応答にもつながる可能性があります。

当レポートでは、世界のmRNAワクチン・治療市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 mRNAワクチン・治療市場レポートのイントロダクション

第2章 mRNAワクチン・治療市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 mRNAワクチン・治療市場の主な要因の分析

  • mRNAワクチン・治療市場の促進要因
  • mRNAワクチン・治療市場の抑制要因と課題
  • mRNAワクチン・治療市場の機会

第5章 mRNAワクチン・治療市場のポーターのファイブフォース分析

第6章 mRNAワクチン・治療市場に対するCOVID-19の影響の分析

第7章 mRNAワクチン・治療の市場レイアウト

  • ワクチンタイプ別
    • 自己増幅型mRNAベースワクチン
    • 従来の非増幅型mRNAベースワクチン
  • エンドユーザー別
    • 病院、診療所
    • 研究開発機関
    • その他
  • 地域
    • 北米のmRNAワクチン・治療の市場規模（2021年～2030年）
    • 欧州のmRNAワクチン・治療の市場規模（2021年～2030年）
    • アジア太平洋のmRNAワクチン・治療の市場規模（2021年～2030年）
    • その他の地域のmRNAワクチン・治療の市場規模（2021年～2030年）

第8章 mRNAワクチン・治療市場の企業と製品のプロファイル

  • Pfizer Inc.
  • BioNTech SE
  • Moderna Inc.
  • Gennova Biopharmaceuticals Limited
  • GSK plc.
  • Daiichi Sankyo
  • Arcturus
  • Boehringer Ingelheim International GmbH
  • Ethris GmbH
  • CureVac SE
  • AIM Vaccine Corporation
  • Charoen Pokphand Group
  • Argos Therapeutics Inc.
  • Sanofi
  • Kernal Biologics Inc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: mRNA Vaccines and Therapeutics Market in Global (2021-2030)
  • Table 4: mRNA Vaccines and Therapeutics Market in Global by Vaccine Type (2021-2030)
  • Table 5: mRNA Vaccines and Therapeutics Market in Global by End-User (2021-2030)
  • Table 6: mRNA Vaccines and Therapeutics Market in Global by Geography (2021-2030)
  • Table 7: mRNA Vaccines and Therapeutics Market in North America (2021-2030)
  • Table 8: mRNA Vaccines and Therapeutics Market in North America by Country (2021-2030)
  • Table 9: mRNA Vaccines and Therapeutics Market in the US (2021-2030)
  • Table 10: mRNA Vaccines and Therapeutics Market in Canada (2021-2030)
  • Table 11: mRNA Vaccines and Therapeutics Market in Mexico (2021-2030)
  • Table 12: mRNA Vaccines and Therapeutics Market in Europe (2021-2030)
  • Table 13: mRNA Vaccines and Therapeutics Market in Europe by Country (2021-2030)
  • Table 14: mRNA Vaccines and Therapeutics Market in France (2021-2030)
  • Table 15: mRNA Vaccines and Therapeutics Market in Germany (2021-2030)
  • Table 16: mRNA Vaccines and Therapeutics Market in the United Kingdom (2021-2030)
  • Table 17: mRNA Vaccines and Therapeutics Market in Italy (2021-2030)
  • Table 18: mRNA Vaccines and Therapeutics Market in Spain (2021-2030)
  • Table 19: mRNA Vaccines and Therapeutics Market in the Rest of Europe (2021-2030)
  • Table 20: mRNA Vaccines and Therapeutics Market in Asia-Pacific (2021-2030)
  • Table 21: mRNA Vaccines and Therapeutics Market in Asia-Pacific by Country (2021-2030)
  • Table 22: mRNA Vaccines and Therapeutics Market in China (2021-2030)
  • Table 23: mRNA Vaccines and Therapeutics Market in Japan (2021-2030)
  • Table 24: mRNA Vaccines and Therapeutics Market in India (2021-2030)
  • Table 25: mRNA Vaccines and Therapeutics Market in Australia (2021-2030)
  • Table 26: mRNA Vaccines and Therapeutics Market in South Korea (2021-2030)
  • Table 27: mRNA Vaccines and Therapeutics Market in Rest of Asia-Pacific (2021-2030)
  • Table 28: mRNA Vaccines and Therapeutics Market in the Rest of the World (2021-2030)
  • Table 29: mRNA Vaccines and Therapeutics Market in the Middle East (2021-2030)
  • Table 30: mRNA Vaccines and Therapeutics Market in Africa (2021-2030)
  • Table 31: mRNA Vaccines and Therapeutics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: mRNA Vaccines and Therapeutics Market in Global (2021-2030)
  • Figure 4: mRNA Vaccines and Therapeutics Market in Global by Vaccine Type (2021-2030)
  • Figure 5: mRNA Vaccines and Therapeutics Market in Global by End-User (2021-2030)
  • Figure 6: mRNA Vaccines and Therapeutics Market in Global by Geography (2021-2030)
  • Figure 7: mRNA Vaccines and Therapeutics Market in North America (2021-2030)
  • Figure 8: mRNA Vaccines and Therapeutics Market in North America by Country (2021-2030)
  • Figure 9: mRNA Vaccines and Therapeutics Market in the US (2021-2030)
  • Figure 10: mRNA Vaccines and Therapeutics Market in Canada (2021-2030)
  • Figure 11: mRNA Vaccines and Therapeutics Market in Mexico (2021-2030)
  • Figure 12: mRNA Vaccines and Therapeutics Market in Europe (2021-2030)
  • Figure 13: mRNA Vaccines and Therapeutics Market in Europe by Country (2021-2030)
  • Figure 14: mRNA Vaccines and Therapeutics Market in France (2021-2030)
  • Figure 15: mRNA Vaccines and Therapeutics Market in Germany (2021-2030)
  • Figure 16: mRNA Vaccines and Therapeutics Market in the United Kingdom (2021-2030)
  • Figure 17: mRNA Vaccines and Therapeutics Market in Italy (2021-2030)
  • Figure 18: mRNA Vaccines and Therapeutics Market in Spain (2021-2030)
  • Figure 19: mRNA Vaccines and Therapeutics Market in the Rest of Europe (2021-2030)
  • Figure 20: mRNA Vaccines and Therapeutics Market in Asia-Pacific (2021-2030)
  • Figure 21: mRNA Vaccines and Therapeutics Market in Asia-Pacific by Country (2021-2030)
  • Figure 22: mRNA Vaccines and Therapeutics Market in China (2021-2030)
  • Figure 23: mRNA Vaccines and Therapeutics Market in Japan (2021-2030)
  • Figure 24: mRNA Vaccines and Therapeutics Market in India (2021-2030)
  • Figure 25: mRNA Vaccines and Therapeutics Market in Australia (2021-2030)
  • Figure 26: mRNA Vaccines and Therapeutics Market in South Korea (2021-2030)
  • Figure 27: mRNA Vaccines and Therapeutics Market in Rest of Asia-Pacific (2021-2030)
  • Figure 28: mRNA Vaccines and Therapeutics Market in the Rest of the World (2021-2030)
  • Figure 29: mRNA Vaccines and Therapeutics Market in the Middle East (2021-2030)
  • Figure 30: mRNA Vaccines and Therapeutics Market in Africa (2021-2030)
  • Figure 31: mRNA Vaccines and Therapeutics Market in South America (2021-2030)
  • Figure 32: Market Drivers
  • Figure 33: Market Barriers
  • Figure 34: Marker Opportunities
  • Figure 35: PORTER'S Five Force Analysis
目次
Product Code: DISR0091

mRNA Vaccines And Therapeutics Market By Vaccine Type (Self-Amplifying Mrna Based Vaccines And Conventional Non-Amplifying mRNA Based Vaccines), By End-User (Hospitals And Clinics, Research And Development Organizations, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising demand for protection against sudden pandemic outbreaks and the increasing patient pool associated with infectious diseases across the globe, among others

The global mRNA Vaccines and Therapeutics market was valued at USD 71,263 million in 2023, growing at a CAGR of -34.01% during the forecast period from 2024 to 2030. The demand for mRNA vaccines and therapeutics is primarily being boosted due to the rising demand for protection against sudden pandemic outbreaks, the increasing patient pool associated with infectious diseases across the globe, the rise in the number of ongoing clinical trials for various indications among others, leading to a positive impact on the market growth during the forecast period from 2024-2030.

mRNA Vaccines And Therapeutics Market Dynamics:

The rising demand for vaccines to protect against sudden pandemic outbreaks such as COVID-19 and to induce immunity among the global population is one of the key factors driving the overall growth of the mRNA vaccine and therapeutics market. COVID-19 vaccines are highly effective at protecting people from getting seriously ill, being hospitalized, and even dying. The mRNA vaccines, owing to their new technology are deemed to be safe and help to create immunity against infectious agents such as viruses, creating an antibody response without experiencing any potentially severe illness.

The viruses constantly change over time, which can lead to the emergence of variants that might have newer characteristics. The vaccines thereby continue to immunize people from developing serious illnesses.

In August 2022, the U.S. Food and Drug Administration (FDA) approved the mRNA COVID-19 vaccine by Pfizer-BioNTech. It was marketed under the name of Comirnaty for the prevention of COVID-19 disease in individuals aged 12 years or older.

In addition, the increasing adoption of mRNA vaccines and therapeutics, owing to the growing awareness, research activities, and funding has allowed big firms to potentially increase their innovative approach, to protect against future disease outbreaks, which is thereby anticipated to propel the overall growth of the mRNA vaccines and therapeutics market in the upcoming years.

However, strict regulatory approvals and the presence of pre-existing vaccines with alternative technologies in the market among others may restrict the mRNA vaccines and therapeutics market growth during the given forecast period.

The COVID-19 pandemic had a positive impact on the market growth of mRNA vaccines and therapeutics as during the peak corona period when coronavirus cases were surging drastically, health institutions and companies were intensely involved in research activities for the development of mRNA vaccines as soon as possible, also receiving funding from various multinational firms and governments to facilitate the vaccine development process. In the initial stages, the shortage of raw and packaging materials, consumables, and equipment owing to lockdown impositions, border closures, and others hindered the production of mRNA vaccines. However, robust research and development activities on the COVID-19 vaccine including those based on mRNA were being conducted by the major companies. Considering the challenge posed by emerging diseases globally on life and the economy owing to their potential to turn into global pandemics (e.g., COVID-19, and others), the research and development of mRNA vaccines are essential as they act as a preventive countermeasure for these diseases. Thereby, post-pandemic arena owing to the introduction of vaccines, resumption of activities in the healthcare and pharmaceutical sector, and rising focus by the governments on strategized plans for further outbreaks, the mRNA vaccine market is expected to grow exponentially during the forecast period.

mRNA Vaccines And Therapeutics Market Segment Analysis:

mRNA Vaccines and Therapeutics market by Vaccine Type (Self-Amplifying mRNA Based Vaccines and Conventional Non-Amplifying mRNA Based Vaccines), End-User (Hospitals and Clinics, Research and Development Organizations, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the vaccine type segment of the mRNA vaccines and therapeutics market, the self-amplifying mRNA-based vaccines category is expected to amass significant revenue share in the year 2023. This is primarily owing to the wide number of advantages and the increasing number of research and development activities in the sector on self-amplifying mRNA-based vaccines.

Self-amplifying mRNA-based vaccines help in easy storage, along with lower costs because its "self-amplifying" design allows them for smaller doses. A self-amplifying mRNA vaccine ideally would replace the two primary doses given during the time of pandemics, giving it an even clearer benefit over its conventional relatives. A booster dose, months later might still be warranted, as is encouraged now for the current mRNA vaccines. The self-amplifying mRNAs could also lead to more durable immune responses.

In June 2022, Gennova Biopharmaceuticals launched its mRNA vaccine for COVID-19 named, Gemcovac-19 which can be stored at temperatures between 2°C and 8°C, and uses the mechanism of self-amplification.

Therefore, owing to the above-mentioned factors, the self-amplifying mRNA-based vaccines category is expected to witness considerable growth, eventually contributing to the overall growth of the global mRNA vaccines and therapeutics market during the forecast period from 2024-2030.

North America is expected to dominate the overall mRNA Vaccines And Therapeutics Market:

Among all the regions, North America is estimated to account for the largest share of the mRNA vaccines and therapeutics market in the year 2023. This domination is owing to the increasing prevalence of infectious diseases, such as COVID-19 infection, new and growing cases of monkeypox, and recent vaccine development activities in the North America region.

According to the CDC (2023), the US reported 6,617 cases of monkeypox till August 2022. The presence of such a huge patient population in the US may trigger research activities by big companies in the region. Along with the recent rise in the cases of monkeypox, vaccine development for monkeypox is further expected to drive the market demand for mRNA vaccines during the forecast period. Additionally, various mRNA vaccine development activities for various diseases in the North America region are also anticipated to expand the vaccine market during the given forecast period.

For example, in August 2022, US FDA announced the first approval of a COVID-19 mRNA vaccine manufactured by Pfizer and BioNTech known as the Pfizer-BioNTech COVID-19 vaccine for individuals 12 years of age and above.

Additionally, as per statistics by the Clinical Trials Government, around 150 mRNA vaccine clinical trials were registered in the United States involving biopharmaceuticals in 2022, thus the increasing number of clinical trials for mRNA vaccines in the region is anticipated to drive the growth of the market.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America mRNA vaccines and therapeutics market during the forecast period.

mRNA Vaccines And Therapeutics Market Key Players:

Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, and others.

Recent Developmental Activities in the mRNA Vaccines And Therapeutics Market:

In March 2023, Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Original Vaccine. The bivalent vaccine is also authorized in this age group as the third dose of a three-dose-primary series.

In December 2022, Biopharmaceutical New Technologies (BioNTech) SE, a global leader in mRNA vaccines, announced that the first subject was dosed in Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1. The first-in-human trial evaluates the safety, tolerability, and immunogenicity of BNT163.

In September 2022, Pfizer Inc. announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability, and immunogenicity of the company's quadrivalent modified influenza mRNA vaccine candidate in approximately 25,000 healthy U.S. adults.

Key Takeaways from the mRNA Vaccines And Therapeutics Market Report Study

Market size analysis for current mRNA Vaccines and Therapeutics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the mRNA Vaccines and Therapeutics market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global mRNA Vaccines and Therapeutics market.

Various opportunities available for the other competitor in the mRNA Vaccines and Therapeutics market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current mRNA Vaccines and Therapeutics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for mRNA Vaccines and Therapeutics market growth in the coming future?

Target Audience who can be benefited from this mRNA Vaccines And Therapeutics Market Report Study

mRNA Vaccines and Therapeutics products providers

Research organizations and consulting companies

mRNA Vaccines and Therapeutics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in mRNA Vaccines and Therapeutics

Various end-users who want to know more about the mRNA Vaccines and Therapeutics market and the latest innovation and developments in the mRNA Vaccines and Therapeutics market.

Frequently Asked Questions for the mRNA Vaccines And Therapeutics Market:

1. What are mRNA Vaccines and Therapeutics?

mRNA vaccines are a new type of vaccine that use a molecule called messenger RNA (mRNA) rather than part of an actual bacteria or virus. Messenger RNA is a type of RNA that is necessary for protein production. Once cells finish making a protein, they quickly break down the mRNA. mRNA from vaccines does not enter the nucleus and does not alter DNA.

2. What is the market for Global mRNA Vaccines and Therapeutics?

The global mRNA Vaccines and Therapeutics market was valued at USD 71,263 million in 2023, growing at a CAGR of -34.01% during the forecast period from 2024 to 2030.

3. What are the drivers for the global mRNA Vaccines and Therapeutics market?

The demand for mRNA Vaccines and Therapeutics is expected to increase substantially due to the rising demand for protection against sudden pandemic outbreaks, the increasing patient pool associated with infectious diseases across the globe, rise in the number of ongoing clinical trials for various indications among others, leading to a positive impact on the market growth during the forecast period from 2024-2030.

4. Who are the key players operating in the global mRNA Vaccines and Therapeutics market?

Some of the key market players operating in the mRNA Vaccines and Therapeutics market include Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, and others.

5. Which region has the highest share in the mRNA Vaccines and Therapeutics market?

North America is expected to dominate the overall mRNA Vaccines and Therapeutics market during the forecast period from 2024-2030. This can be ascribed to the increasing prevalence of infectious diseases, such as COVID-19 infection, new and growing cases of monkeypox, and recent vaccine development activities in the North America region.

Table of Contents

1. mRNA Vaccines and Therapeutics Market Report Introduction

2. mRNA Vaccines and Therapeutics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. mRNA Vaccines and Therapeutics Market Key Factors Analysis

  • 4.1. mRNA Vaccines and Therapeutics Market Drivers
    • 4.1.1. Rising demand for protection against sudden pandemic outbreaks
    • 4.1.2. Increasing patient pool associated with infectious diseases across the globe
    • 4.1.3. Rise in the number of ongoing clinical trials for various indications
  • 4.2. mRNA Vaccines and Therapeutics Market Restraints and Challenges
    • 4.2.1. Strict regulatory approvals
    • 4.2.2. Presence of pre-existing vaccines with alternative technologies in the market
  • 4.3. mRNA Vaccines and Therapeutics Market Opportunities
    • 4.3.1. Increasing research and development activities on mRNA vaccines
    • 4.3.2. The increasing number of investments and funding by governments and market players

5. mRNA Vaccines and Therapeutics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on mRNA Vaccines and Therapeutics Market

7. mRNA Vaccines and Therapeutics Market Layout

  • 7.1. By Vaccine Type
    • 7.1.1. Self-amplifying mRNA-Based Vaccines
    • 7.1.2. Conventional Non-Amplifying mRNA-Based Vaccines
  • 7.2. By End-User
    • 7.2.1. Hospitals and Clinics
    • 7.2.2. Research and Development Organizations
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.1.1. United States mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.1.2. Canada mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.1.3. Mexico mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
    • 7.3.2. Europe mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.1. France mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.2. Germany mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.3. United Kingdom mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.4. Italy mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.5. Spain mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.2.6. Rest of Europe mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
    • 7.3.3. Asia-Pacific mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.1. China mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.2. Japan mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.3. India mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.4. Australia mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.5. South Korea mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.3.6. Rest of Asia-Pacific mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
    • 7.3.4. Rest of the World (RoW) mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.4.1. Middle East mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.4.2. Africa mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)
      • 7.3.4.3. South America mRNA Vaccines and Therapeutics Market Size in USD million (2021-2030)

8. mRNA Vaccines and Therapeutics Market Company and Product Profiles

  • 8.1. Pfizer Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. BioNTech SE
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Moderna Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Gennova Biopharmaceuticals Limited
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. GSK plc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Daiichi Sankyo
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Arcturus
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Boehringer Ingelheim International GmbH
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Ethris GmbH
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. CureVac SE
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. AIM Vaccine Corporation
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Charoen Pokphand Group
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Argos Therapeutics Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Sanofi
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Kernal Biologics Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us